Publicacions
El coneixement generat a IrsiCaixa es comparteix amb la comunitat científica a través de la publicació d’articles a revistes científiques d’alt impacte.
Prevalence of etravirine-associated mutations in clinical samples with resistance to nevirapine and efavirenz.
Drug-resistance mutations number and K70R or T215Y/F substitutions predict treatment resumption during guided treatment interruptions.
Genetic and catalytic efficiency structure of an HCV protease quasispecies.
Clinical approach to drug resistance interpretation: expert advice.
Antiretroviral therapy interruption guided by CD4 cell counts and plasma HIV-1 RNA levels in chronically HIV-1-infected patients.
Unexpected CD4 cell count decline in patients receiving didanosine and tenofovir-based regimens despite undetectable viral load.
Alternation of antiretroviral drug regimens for HIV infection. Efficacy, safety and tolerability at week 96 of the Swatch Study.
New antiretroviral drugs and approaches to HIV treatment.
Role of structured treatment interruption before a 5-drug salvage antiretroviral regimen: the Retrogene Study.
Virological, immunological, and clinical impact of switching from protease inhibitors to nevirapine or to efavirenz in patients with human immunodeficiency virus infection and long-lasting viral suppression.